


CLAIM AMENDMENTS


This listing of claims will replace all prior versions and listings of claims in the application:

1. (currently amended) Atorvastatin calcium Form V ~~or hydrate thereof~~ of claim 3 produced by a process comprising the steps of
 - a) dissolving a metal, ammonium or alkylammonium salt of atorvastatin in a solvent to form an atorvastatin salt solution,
 - b) contacting the atorvastatin salt solution with a calcium salt, and
 - c) isolating crystalline atorvastatin calcium Form V ~~or hydrate thereof~~.
2. (currently amended) Atorvastatin calcium Form V ~~or hydrate thereof~~ having an X-ray powder diffractogram substantially as follows



3. (currently amended) Atorvastatin calcium Form V ~~and hydrates thereof~~ characterized by X-ray powder diffraction peaks at 5.3 ± 0.2 and 8.3 ± 0.2 degrees 2θ and a broad peak at $18-23 \pm 0.2$ degrees 2θ with a maximum at 18.3 ± 0.2 degrees 2θ .

4. (currently amended) Atorvastatin calcium Form V ~~or hydrate thereof~~ having a solid state ^{13}C NMR spectrum ~~substantially~~ as follows



5. (currently amended) Atorvastatin calcium Form V ~~and hydrates thereof~~ characterized by solid state ^{13}C NMR signals at 21.9, 25.9, 118.9, 122.5, 128.7, 161.0 and 167.1 ppm.
6. (previously presented) Atorvastatin calcium Form V of claim 3 containing up to about 9 moles of water per mole of atorvastatin calcium.

7.-15. (canceled)

16. (currently amended) A pharmaceutical composition that is a solid or suspension comprising a therapeutic amount of atorvastatin calcium Form V ~~or hydrates thereof~~ of claim 1, 3, or 5.

17. (currently amended) Atorvastatin calcium Form V ~~and hydrates thereof~~ characterized by x-ray powder diffraction peaks at 5.3 ± 0.2 and 8.3 ± 0.2 degrees 2θ and ^{13}C NMR signals at 21.9, 25.9, 118.9, 122.5, 128.7, 161.0 and 167.1 ppm.

18.-19. (canceled)